drug · antibody
OPDIVO QVANTIG
updated 6mo agoby $BMY BRISTOL MYERS SQUIBB CO🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 8- drugOPDIVO356 co-mentions · 92 sources
- drugnivolumab356 co-mentions · 92 sources
- tagApproval352 co-mentions · 88 sources
- company$BMYBRISTOL MYERS SQUIBB CO166 co-mentions · 83 sources
- company$CELG-RIBRISTOL MYERS SQUIBB CO166 co-mentions · 83 sources
- companyBristol-Myers Squibb Co12 co-mentions · 6 sources
- drug(hyaluronidase (recombinant, human) + nivolumab)10 co-mentions · 5 sources
- tagOncology10 co-mentions · 3 sources
Antibody drug with a maximum clinical stage of Approval (across all indications), with 15 approved and 112 investigational indications.
targets
Programmed cell death protein 1
all catalysts(0)
nothing on the calendar yet
Trials studying OPDIVO QVANTIG
- phase2Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
- phase2Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
- phase3A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- phase2Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
- —Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy
- phase3A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- phase2Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
- phase2Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
News(10)
- BMS R&D head to depart amid restructureBristol Myers Squibb is combining all research and development efforts under one leader as pressure rises to replenish its pipeline.biospace · 4d ago
- Bayer wins first-in-class FDA nod for blood thinner, setting stage for BMS-J&J rivalBayer’s Sunharbo has secured the first FDA approval of its class, establishing a regulatory pathway for other factor XIa inhibitors, such as Bristol Myers Squibb and Johnson and Johnson’s milvexian.biospace · 6d ago
- BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beatIn addition to canning an Orum-acquired blood cancer candidate last month, Bristol Myers Squibb cut a Prothena-partnered neuro asset in the third quarter. But with sales climbing 7%, the Big Pharma…biospace · 18d ago
- ESMO 2026: Analysts warm to Merck, Moderna’s cancer vaccine after frustrating data leakAfter sitting through the full presentation on the Phase 3 INTerpath-001 trial at the ESMO Congress over the weekend, analysts are more keen on the personalized mRNA cancer vaccine data that last w…biospace · 21d ago
- J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutbackJohnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating its $4.1 billion RayzeBio bu…biospace · 1mo ago
- BMS’ Phase 3 win for lung drug clouded by high-dose missA low-dose win could derisk a regulatory pathway for BMS’ LPA1 antagonist in idiopathic pulmonary fibrosis after a recently reported patient death, but a miss at the higher dose leaves analysts awa…biospace · 1mo ago
- BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growthBristol Myers Squibb has reported phase 3 wins in a lung disease and a solid tumor, taking two steps on its path toward post-patent cliff growth.fiercebiotech · 1mo ago
- Ono pays $80M for regional rights to trio of Biohaven IgG degraders, including phase 3 Grave’s assetJapan’s Ono Pharmaceutical is paying $80 million upfront for the regional rights to a trio of Biohaven’s IgG degraders, led by a phase 3-stage Grave’s disease prospect.fiercebiotech · 1mo ago
- Q3 layoffs down YOY, with 90% fewer biopharma employees affectedBig Pharma companies including Bristol Myers Squibb, Johnson & Johnson and Novartis are among those that made or planned layoffs in Q3. Those cuts could affect over 1,800 employees, with New Jersey…biospace · 1mo ago
- Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trialA Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture cash.biopharma_dive · 1mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that